Andrew Dunlop

Specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of therapeutic products

Develops novel therapeutics and drug delivery technologies

Develops drugs for the treatment of inflammatory skin diseases and conditions

Operates as clinical-stage biotechnology company, which develops non-viral gene therapies

Develops therapeutics and drug delivery technologies to address chronic inflammatory diseases

Functions as a College/University

New Vantage Group seeks investment in companies located in the United States primarily in Washington, DC. The firm focuses on board range of sectors and industries. It provides financing for early-stage transactions.

MASA focuses on private equity investments in a variety of sectors including biotechnology, consumer products, energy, environmental technology, financial services, healthcare, infrastructure, new media, real estate, sports/recreation, telecommunications, transportation and nanotechnology. They invest in the US, Europe, Latin America, Israel, Japan, Russia, South Korea and West Africa. Their investments are across the capital structure including seed stage, mezzanine financings and buyouts.

MASA Life Science Ventures invests in early-stage companies located in the United States, Canada, Europe and Israel. The firm targets companies operating in the fields of bio-therapeutics, medical devices, medical diagnostics, healthcare and bio-IT.